The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer

被引:0
作者
Noriko Goda
Shinsuke Sasada
Hideo Shigematsu
Norio Masumoto
Koji Arihiro
Hiroyoshi Nishikawa
Shimon Sakaguchi
Morihito Okada
Takayuki Kadoya
机构
[1] Hiroshima University,Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine
[2] National Hospital Organization Kure Medical Center and Chugoku Cancer Center,Department of Breast Surgery
[3] Hiroshima University,Department of Anatomical Pathology
[4] Osaka University,Experimental Immunology, WPI Immunology Frontier Research Center
[5] Division of Cancer Immunology,Department of Immunology
[6] Exploratory Oncology Research and Clinical Trial Center,undefined
[7] National Cancer Center,undefined
[8] Nagoya University Graduate School of Medicine,undefined
来源
Discover Oncology | / 13卷
关键词
Breast cancer; Regulatory T cell; Tumor-infiltrating lymphocyte; FOXP3; CD8; Neoadjuvant chemotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 211 条
[1]  
Ghoncheh M(2016)Incidence and mortality and epidemiology of breast cancer in the world Asian Pac J Cancer Prev 17 43-46
[2]  
Pournamdar Z(2016)Clinical relevance of host immunity in breast cancer: from TILs to the clinic Nat Rev Clin Oncol 13 228-241
[3]  
Salehiniya H(2014)Tumor-infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial Ann Oncol 25 1544-1550
[4]  
Savas P(2018)Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy Lancet Oncol 19 40-50
[5]  
Salgado R(2016)Clinical significance of tumor-infiltrating lymphocytes in breast cancer J Immunother Cancer 4 59-251
[6]  
Denkert C(2017)Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: Part 1: assessing the host immune response, tils in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research Adv Anat Pathol 24 235-787
[7]  
Sotiriou C(2008)Reguratory T cell and immune tolerance Cell 133 775-500
[8]  
Darcy PK(2010)FOXP3+ regulatory T cell in the human immune system Nat Rev Immunol 10 490-7
[9]  
Smyth MJ(2010)Regulatory T cells in cancer immunotherapy Curr Opin Immunol 27 1-278
[10]  
Loi S(2009)A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer Oncol Rep 22 273-1280